Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) - CYTO STOCK NEWS

Altamira Therapeutics (Nasdaq:CYTO) has announced the publication of a preclinical study demonstrating effective treatment of abdominal aortic aneurysm (AAA) using their SemaPhore™ nanoparticles to deliver SOD2 mRNA. The study, conducted by researchers from Washington University and the University of South Florida, showed significant reduction in aorta dilation (p<0.05), delayed rupture, and highly significant improvement in survival rates (p<0.01) compared to untreated controls in an AAA mouse model.

The treatment approach targets oxidative stress by boosting mitochondrial SOD2 expression, reducing levels of reactive oxygen species (ROS). This nanotherapeutic mRNA delivery method may have potential applications in managing small AAAs and preventing ruptures, which are often life-threatening.

Altamira Therapeutics, under the stock ticker CYTO, has highlighted a newly published review supporting the use of betahistine for managing residual dizziness in benign paroxysmal positional vertigo (BPPV) patients. The review, appearing in Frontiers in Neurology, suggests that betahistine, which is commonly used outside the US, can significantly reduce dizziness following physical repositioning procedures. Altamira is developing a nasal spray formulation called AM-125, which offers higher bioavailability than oral betahistine. The company aims to partner or divest AM-125 as it pivots towards RNA delivery technology. BPPV is the most common type of vertigo, affecting 17-42% of diagnosed vertigo cases and costing the US healthcare system around $2 billion annually.

Altamira Therapeutics provided a business update, highlighting significant improvements in RNA nanoparticle stability, which are now stable in liquid form at 4°C for at least three weeks and can withstand shaking stress.

The company is pursuing partnerships for its AM-125 nasal spray for vertigo and other CNS disorders. AM-125 has shown promising Phase 2 trial results in Europe and potential for multiple CNS applications.

Altamira is streamlining its corporate structure, merging subsidiaries and switching its financial reporting from Swiss Francs to US Dollars to better align with its strategic focus and investor base.

Altamira Therapeutics announced the dissemination of positive results from its NASAR clinical trial for Bentrio nasal spray in treating seasonal allergic rhinitis (SAR). The trial's results, published in the Allergy journal's social media channels, showed significant efficacy and safety. The study, involving 100 patients in Australia, met its primary endpoint by significantly reducing the mean daily reflective Total Nasal Symptom Score (rTNSS) compared to saline (p = 0.013). Secondary endpoints also showed significant improvements in quality of life and global efficacy ratings (p < 0.001). Altamira expects Bentrio's sales to grow significantly with planned launches in new markets in 2024.

Altamira Therapeutics has filed a provisional patent application for OligoPhore nanoparticles with siRNA targeting p65 protein for the treatment of cancer and inflammation. The company aims to expand its IP portfolio focusing on RNA delivery technology, particularly for rheumatoid arthritis. The innovative approach utilizes siRNA to silence p65, a key protein involved in cancer and inflammatory diseases, including rheumatoid arthritis. Altamira's AM-411 program demonstrates promising results by delivering siRNA to inflamed tissues, offering potent treatment effects with reduced side effects and treatment resistance risks. Rheumatoid arthritis affects millions globally, with no cure currently available, making the development of effective treatments crucial.

Altamira Therapeutics announces positive results from the Bentrio trial in seasonal allergic rhinitis, with statistically significant improvements in nasal symptoms, quality of life, and reduced need for relief medication. The publication in a top peer-reviewed journal validates the effectiveness and safety of Bentrio, supporting plans for international expansion.

Altamira Therapeutics reports a successful year with a focus on RNA delivery technology, collaborations, and financial improvements. The company achieved an 85% reduction in net loss, eliminated financial debt, and increased shareholders' equity by CHF 14.8 million. Altamira is progressing with preclinical development of RNA delivery platforms for extrahepatic targets, showcasing promising results in cancer and osteoarthritis. Strategic collaborations with Heqet Therapeutics and Univercells Group aim to utilize Altamira's technology for heart tissue regeneration and mRNA vaccine delivery. The company is advancing development programs for KRAS-driven tumors and rheumatoid arthritis, with plans for IND filings in 2025. Altamira divested a stake in its subsidiary, Altamira Medica AG, for cash consideration and financial gain. The subsidiary's key asset, Bentrio nasal spray, demonstrated superior efficacy in allergic rhinitis treatment. Altamira is also focusing on partnering its inner ear therapeutics assets, particularly AM-125 for acute vestibular syndrome.

Altamira Therapeutics (CYTO) to host Full Year 2023 Financial Results and Business Update Call on April 10, 2024. Founders and executives to provide insights on company performance and future plans.

Altamira Therapeutics partners with Univercells Group to evaluate the use of its SemaPhore platform for delivering mRNA vaccines, aiming for safer and more accessible vaccination methods. The collaboration aims to test a proprietary mRNA vaccine using Altamira's nanoparticle technology. If successful, a commercial agreement for manufacturing nanoparticle-based mRNA vaccines may follow.